The DMXL1 Knockout NCI-H1975 Polyclonal Cells offer a powerful CRISPR/Cas9-edited polyclonal knockout cell population for investigating the functional roles of DMXL1 in biomedical research. This heterogeneous knockout pool was generated by transfecting NCI-H1975 cells with CRISPR/Cas9 reagents targeting the DMXL1 locus, resulting in a population carrying diverse loss-of-function mutations across the target gene. The polyclonal format provides a robust and representative model for studying DMXL1-dependent phenotypes while mitigating clonal artifacts, making it ideal for pathway analysis, drug-screening campaigns, and mechanism-of-action studies where population-level responses are critical.
This model leverages the well-characterized NCI-H1975 human lung adenocarcinoma epithelial cell line, which harbors activating EGFR mutations (L858R and T790M) and was originally derived from the pleural fluid of a non-smoker female patient. As a widely used model for EGFR-mutant non-small cell lung cancer, NCI-H1975 cells recapitulate key oncogenic signaling features that drive tumor progression and acquired resistance to first- and third-generation EGFR inhibitors. The integration of DMXL1 knockout into this genetically defined background thus enables researchers to dissect how endocytic trafficking and metabolic signaling crosstalk with oncogenic pathways in a clinically relevant context.
DMXL1 is a large scaffold protein that functions as a critical component of the Rabconnectin-3 complex, which governs the assembly, stability, and activity of the vacuolar ATPase (V-ATPase) proton pump. Through its interaction with Rab3a and V-ATPase subunits such as ATP6V0A1 and ATP6V1A, DMXL1 directly regulates endolysosomal acidification, thereby coupling intra-luminal pH to downstream nutrient-sensing cascades. In response to fluctuations in endolysosomal pH and nutrient status, DMXL1-dependent modulation of V-ATPase activity controls the recruitment and activation of mTORC1 via the Ragulator?CRag GTPase complex. Consequently, DMXL1 acts as a key node linking vesicular trafficking to mTORC1-driven processes, including autophagic degradation, lysosomal biogenesis, and synaptic vesicle cycling. Loss of DMXL1 disrupts this coordination, leading to profound defects in lysosomal acidification, impaired mTORC1 re-activation upon nutrient replenishment, and aberrant autophagic flux.
Within the NCI-H1975 cell context, DMXL1 knockout provides a unique tool to probe how V-ATPase?CmTORC1 crosstalk influences EGFR-mutant lung adenocarcinoma biology. Given the established role of mTORC1 hyperactivation in driving therapy resistance and metabolic reprogramming in EGFR-driven tumors, perturbing DMXL1 may reveal vulnerabilities related to endosomal trafficking and pH homeostasis. Researchers can employ this polyclonal model to assess whether DMXL1 loss sensitizes cells to mTOR kinase inhibitors (e.g., rapamycin, everolimus) or EGFR-targeted agents, and to investigate the interplay between endocytic pathways, autophagy-mediated survival mechanisms, and tumor cell proliferation. The system is also pertinent for studying how DMXL1-dependent pH regulation impacts the processing and degradation of cell surface receptors and signaling molecules.
Typical research applications encompass a broad range of functional assays: Western blotting to evaluate DMXL1 expression alongside mTORC1 readouts (phospho?S6K, phospho?4EBP1); immunofluorescence localization of lysosomal markers (LAMP1, LAMP2) and LC3 puncta; co?immunoprecipitation of V?ATPase subunits to probe complex integrity; lysosomal pH measurements using ratiometric dyes; and autophagy flux quantification via bafilomycin A1 treatment. The polyclonal population is also amenable to high?throughput drug screens, RNA?seq transcriptome profiling, and genetic complementation studies. For further information or to discuss customized applications, please contact Ascent Research.
